

[PDF] Successful treatment of a patient with Li-Fraumeni ...

<https://www.tandfonline.com/doi/pdf/10.4161/cbt.29173>

We report the case of a young, never-smoker woman with Li-Fraumeni syndrome and advanced lung adenocarcinoma refractory to multiple lines of conventional chemotherapy and negative for actionable alterations by routine testing. Comprehensive genomic profiling by clinical-grade next generation sequencing was performed on 3320 exons of 184

Olaparib combined with immunotherapy for treating a ...

https://journals.lww.com/md-journal/Fulltext/2020/09180/Olaparib_combined_with...

The next-generation sequencing identified a BRCA2 germline mutation in this patient. A poly (ADP-ribose) polymerase inhibitor, olaparib, plus nivolumab therapy was started and achieved stable disease. Outcomes: The patient achieved stable disease and improvement in hepatalgia for 3 months after the combination treatment of Olaparib and nivolumab.

PEOPLE ALSO ASK

- How does olaparib work to treat breast cancer? ▾
- Which is better for pancreatic cancer pembrolizumab or olaparib? ▾
- What are the functions of BRCA1 and BRCA2? ▾
- Which is better radiation therapy with or without olaparib? ▾

Feedback

Treatment with olaparib monotherapy for BRCA2-mutated ...

<https://www.dovepress.com/treatment-with-olaparib...>

The clinical record of a patient with BRCA2-mutated refractory advanced ICC treated with olaparib was analyzed. The patient was administered with olaparib (400 mg orally twice daily) and followed up for 11 months. The clinical tumor response was evaluated after 4 weeks of olaparib treatment, and then every 8 weeks (two treatment cycles).

Cited by: 3 Author: Yuan Cheng, Juan Zhang, Shu kui Qin, H...
Publish Year: 2018

12,200 Results Any time ▾

[PDF] [Successful treatment of a patient with Li-Fraumeni ...](#)

<https://www.tandfonline.com/doi/pdf/10.4161/cbt.29173>

our patient.^{2,3} The ERBB2 S310F **mutation** is a recently discov-ered **mutation** identified by a comprehensive genetic study.⁴ Up until now 10 cancer cases have been reported in the literature, 3 in **lung**, 2 in large intestine, 1 in stomach, 1 in urinary tract, 2 in breast, and 1 in ovarian.^{2,4-9} We **report** a fascinating **case** of a young, non-smoker ...

Created Date: 7/31/2014 9:57:08 AM

[PDF] [Successful treatment of refractory high-grade serous ...](#)

<https://theoncologist.onlinelibrary.wiley.com/doi/...>

Successful Treatment of Patients with **Refractory** High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: **A Case Report** DAPENG DONG, a,b GE SHEN,a,b YONG DA,a,b MING ZHOU,a,b GANG YANG,a,b MINGMING YUAN,c RONGRONG CHENc aDepartment of Oncology, Beijing Hui 'an Hospital of Integrated Traditional Chinese and Western Medicine, Beijing, People's Republic

People also ask

- How are BRCA1 and BRCA2 mutations linked to cancer? ▾
- How are PARP inhibitors used to treat BRCA mutations? ▾
- Are there any therapies for women with BRCA mutations? ▾

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 63419

Manuscript Type: CASE REPORT

Successful treatment of refractory lung adenocarcinoma harboring a germline *BRCA2* mutation with olaparib: A case report

Zhang L. *et al.* Olaparib in NSCLC with *BRCA2* mutations

Abstract

BACKGROUND

In recent years, targeted therapy and immunotherapy have become important treatment strategies for patients with non-small cell lung cancer (NSCLC). However, the clinical evidence for successful off-label use of targeted drugs for patients with NSCLC following progression on multiple lines of treatment is still lacking.

CASE SUMMARY

Match Overview

Match #	Match Type	Words	Percentage
1	Crossref	38 words Dapeng Ding, Ge Shen, Yong Da, Ming Zhao, Gang Yang, Mingming Yuan, Rongrong Chen. "Successful Treatment ..."	2%
2	Crossref	23 words Christina R. Washington, Kathleen N. Moore. "PARP Inhibi ... ors in the treatment of ovarian cancer", <i>Current Opinion in</i>	1%
3	Internet	21 words www.ncbi.nlm.nih.gov	1%
4	Internet	18 words crawled on 03-Mar-2021 www.unboundmedicine.com	1%
5	Internet	15 words crawled on 30-Jul-2020 worldwidescience.org	1%
6	Internet	15 words crawled on 25-Aug-2020 www.wjgnet.com	1%
7	Internet	12 words crawled on 07-Dec-2020 kci.pure.kcl.ac.uk	1%
8	Internet	12 words crawled on 08-Apr-2016 topics.scienceirect.com	1%

国内版 国际版

Successful treatment of refractory lung adenocarcinoma harboring



ALL IMAGES VIDEOS

12,300 Results Any time ▾

[PDF] Successful treatment of a patient with Li-Fraumeni ...

<https://www.tandfonline.com/doi/pdf/10.4161/cbt.29173>

We report the case of a young, never-smoker woman with Li-Fraumeni syndrome and advanced lung adenocarcinoma refractory to multiple lines of conventional chemotherapy and negative for actionable alterations by routine testing. Comprehensive genomic profiling by clinical-grade next generation sequencing was performed on 3320 exons of 184

Created Date: 7/31/2014 9:57:08 AM

[PDF] Successful treatment of refractory high-grade serous ...

<https://theoncologist.onlinelibrary.wiley.com/doi/...>

Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report DAPENG DONG, a,b GE SHEN,a,b YONG DA,a,b MING ZHOU,a,b GANG YANG,a,b MINGMING YUAN,c RONGRONG CHENc aDepartment of Oncology, Beijing Hui 'an Hospital of Integrated Traditional Chinese and Western Medicine, Beijing, People's ...

PEOPLE ALSO ASK

How are BRCA1 and BRCA2 mutations linked to cancer? ▾

How are PARP inhibitors used to treat BRCA mutations? ▾

Are there any clinical trials for Olaparib in pancreatic cancer? ▾

How are azd6738 and olaparib used in cancer treatment? ▾

Feedback

Successful Treatment of Patients with Refractory High ...

<https://theoncologist.onlinelibrary.wiley.com/doi/...>

Jul 11, 2020 · Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report Dapeng Dong, Department of Oncology, Beijing Hui 'an Hospital of Integrated Traditional Chinese and Western Medicine, Beijing, People's Republic of China

Crizotinib 1 Author: Dapeng Dong, Ge Shen, Yong Da, Ming Z...